Herborium Group, Inc. Commences the Sale of AcnEase, its Herbal Acne Treatment

Herborium Group, Inc. (PINKSHEETS: HBRM), a botanical therapeutics(R) company that develops, licenses and markets novel botanical ingredients-based medicinal products, announced today that it has entered the German market with its proprietary AcnEase(R) medicine for the treatment of Acne and Rosacea. AcnEase represents, possibly, one of the most important product introductions into the field of Acne treatment in the last several decades since it is the only 100% systemic, all-herbal medicine that demonstrated success rates of approximately 95% in clinical studies. The German market is the largest in Europe for natural-based medicinal products (over $30 billion) and is also a very large market for Dermatologics, in particular acne products, with expected sales of over $3 billion in 2013.

"In recent years, the level of innovation in the area of dermatologic acne treatment has dwindled. This has caused an erosion of the market share of several leading players. As major brands continue to lose ground to smaller, specialized players, opportunities are being created for companies like Herborium that can provide novel medicinal alternatives and implement effective lifecycle management, thereby accessing lucrative revenues," notes Dr. Agnes P. Olszewski, CEO of Herborium. "With our presence in the UK and now in Germany, in addition to our strong presence in the US market, Herborium is certainly going to take advantage of these opportunities," adds Dr. Olszewski.

For more information about Herborium and AcnEase visit the following links: www.herborium.com and www.acnease.com

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics(R) company, is focused on developing, licensing, and marketing proprietary, botanical-based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to Western markets. The company has secured a pipeline of botanical ingredients-based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Sunrise Consulting Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.